Physician profile
Aisha Taylor
NPI 1336467414
$29,273.91
in general payments reported to CMS, 2019-2025
30 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Urogynecology and Reconstructive Pelvic Surgery (Urology) provider received nationally (typical 2025 total: $782).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $656 · 2021: $19K · 2022: $7,093 · 2023: $140 · 2024: $2,014 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,982 · Food and Beverage: $302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,981.62 |
| Food and Beverage | $302.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $27,365.21 | 2020-2024 | Axonics, Bulkamid |
| Janssen Biotech, INC. | $260.68 | 2019-2023 | Erleada, Akeega |
| Endo Pharmaceuticals INC. | $176.66 | 2020-2022 | |
| Allergan, INC. | $171.04 | 2019-2022 | |
| Urovant Sciences INC | $128.45 | 2021-2022 | |
| Boston Scientific Corporation | $122.92 | 2019-2025 | Axonics |
| Caldera Medical, INC | $116.65 | 2022 | |
| Astellas Pharma US INC | $111.72 | 2019-2022 | |
| Antares Pharma, INC. | $111.04 | 2019-2022 | |
| Tolmar Pharmaceuticals, INC. | $95.04 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $76.21 | 2021-2022 | |
| Abbvie INC. | $53.55 | 2025 | |
| Merck Sharp & Dohme LLC | $52.47 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $44.28 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $43.54 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $36.94 | 2019 | |
| Applied Medical Resources Corporation | $32.37 | 2024 | |
| 180 Medical, INC. | $28.44 | 2019 | |
| Neotract INC. | $26.54 | 2019-2020 | |
| Convatec INC. | $26.51 | 2021 | |
| Amgen INC. | $26.27 | 2021-2022 | |
| Valencia Technologies Corporation | $26.01 | 2025 | Ecoin Device Kit |
| Contura, INC. | $24.24 | 2020 | |
| Travere Therapeutics, INC. | $23.50 | 2021 | |
| Sumitomo Pharma America, INC. | $18.66 | 2023 | Gemtesa |
| Blue Earth Diagnostics | $17.02 | 2021 | |
| Photocure INC | $16.07 | 2025 | Cysview |
| Femselect INC. | $14.54 | 2022 | |
| Angiodynamics, INC. | $14.08 | 2022 | |
| Pfizer INC. | $13.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aisha Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.